A Randomized, Double-blind, Multi-dose, Placebo-controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate to Severe Chronic Low Back Pain

Trial Profile

A Randomized, Double-blind, Multi-dose, Placebo-controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate to Severe Chronic Low Back Pain

Suspended
Phase of Trial: Phase II/III

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Fasinumab (Primary) ; Fasinumab (Primary)
  • Indications Back pain
  • Focus Therapeutic Use
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 26 Jul 2017 This trial status has been changed from Suspended to completed in Denmark as per European Clinical Trials Database record.
    • 16 Nov 2016 Planned End Date changed from 1 Jun 2017 to 1 Jul 2017.
    • 16 Nov 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top